SR9009 (Stenabolic)
Aliases: Stenabolic
Last verified: 2026-09-23
The short version
A REV-ERBα agonist — modulates the circadian clock and metabolism: in mice reduces fat, increases endurance. No human studies; poor oral bioavailability. Key fact: No controlled human trials exist. Everything known about SR9009 (Stenabolic) in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; WADA-banned (S4).
Identity & type
- Molecular type
- mali molekul
- Origin
- A REV-ERBα agonist — modulates the circadian clock and metabolism: in mice reduces fat, increases endurance.
Mechanism of action
REV-ERBα agonism → repression of lipogenic genes, increased mitochondrial activity.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for SR9009 (Stenabolic). Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 10–40 mg/day split (questionable bioavailability). Energy and metabolic "speed-up" are reported, but effects vary due to poor oral bioavailability; often disappointing.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Energy and metabolic "speed-up" are reported, but effects vary due to poor oral bioavailability; often disappointing.
Protocol — official vs community
Official / label
No approved product. Poor oral bioavailability in preclinical work drove the development of improved analogues (SR9011, SLU-PP-332).
Duration: —
The 'exercise in a pill' headlines ran far ahead of the pharmacokinetics.
Community (anecdotal)
10–30 mg oral daily, split dosing due to short half-life; some hold under the tongue.
- Cycle:
- 8 weeks.
- Break:
- 4 weeks.
Half-life-driven split dosing three times a day is the compliance-killer of this compound.
Human evidence
No controlled human trials exist. Everything known about SR9009 (Stenabolic) in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical (Scripps); never clinical.
Known risks
- Unknown in humans; theoretical circadian disruption.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.